George Abercrombie joins Ziopharm's board
This article was originally published in Scrip
Ziopharm Oncology (US) has appointed George Abercrombie to its board of directors. He will also serve as a member of the board’s compensation committee, as well as the nominating and corporate governance committee. The company has also elected Dr Murray Brennan chairman of the board. Mr Abercrombie most recently served as president and CEO of Roche North America and has more than 30 years' experience in the pharmaceutical industry. Before joining Roche in 2001, Mr Abercrombie was senior vice-president of commercial operations at Glaxo Wellcome.
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.